Combination of breast imaging parameters obtained from F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer.

Date publication

avril 2019

Journal

European journal of radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BRUNOTTE François , Pr COUTANT Charles , Dr LADOIRE Sylvain , Pr COCHET Alexandre

Tous les auteurs :
Grapin M, Coutant C, Riedinger JM, Ladoire S, Brunotte F, Cochet A, Humbert O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30927964

Résumé

The luminal/Human Epidermal growth factor Receptor 2 (HER2) negative subtype of breast cancer has low chemo-sensitivity. When neoadjuvant chemotherapy (NAC) is indicated in this subtype, before a possible breast-conserving surgery (BCS), it is more reasonable to target tumor shrinkage than complete pathological tumor response. We aimed to identify breast and tumor Fluoro-deoxy-glucose (F-FDG) PET-CT scan imaging features for the early prediction of BCS after NAC in luminal/HER2 negative subtypes of breast cancer.

Référence

Eur J Radiol. 2019 Apr;113:81-88